A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes
Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
To determine if an intravitreal sustained release dexamethasone implant (Ozurdex®) injected
at the conclusion of surgery in patients undergoing vitrectomy and membrane peeling for
idiopathic epiretinal membranes is safe and effective to decrease the macular edema, as
demonstrated by a gain in vision and decreased in retinal thickness and volume.
Phase:
N/A
Details
Lead Sponsor:
Sunnybrook Health Sciences Centre
Collaborators:
Allergan St. Michael's Hospital, Toronto Unity Health Toronto